<--- Back to Details
First PageDocument Content
Clinical research / Research / Pharmaceuticals policy / Drug discovery / Pharmacovigilance / Regulatory requirement / Food and Drug Administration / Clinical trial / Good Clinical Practice / Pharmaceutical sciences / Pharmacology / Pharmaceutical industry
Date: 2012-06-22 04:07:06
Clinical research
Research
Pharmaceuticals policy
Drug discovery
Pharmacovigilance
Regulatory requirement
Food and Drug Administration
Clinical trial
Good Clinical Practice
Pharmaceutical sciences
Pharmacology
Pharmaceutical industry

Microsoft PowerPoint - k-2- Risk Management.ppt

Add to Reading List

Source URL: www.ich.org

Download Document from Source Website

File Size: 129,52 KB

Share Document on Facebook

Similar Documents

SL-35: Oncology Phenotypic Screening. Macrocycles. Phenotypic screening is a firmly established technology that has contributed to the identification of valuable therapeutic agents in oncology drug discovery [1]. For exa

DocID: 1voSH - View Document

Seminars on Drug Discovery & Development Wednesdays 17::00, Lecture Hall 1, Pharmazentrum, Klingelbergstrasse 50, Basel Feb 24, 16 Prof. Dr. G. Klebe, Institute of Pharmaceutical Chemistry, Philipps-University Mar

DocID: 1vnYL - View Document

THE SCIENCE OF BETTER MEDICINES The Harvard Program in Therapeutic Science (HiTS) is building partnerships and developing new ideas and technologies to advance drug discovery and precision medicine.

DocID: 1vnKo - View Document

Scientific Program conferenceseries.com 3rd International Conference and Expo on Drug Discovery & Designing

DocID: 1vngF - View Document

5th CDDD Meeting COMPUTATIONALLY DRIVEN DRUG DISCOVERY November 16-17, 2017 | IFOM, Milan - Italy

DocID: 1vkVj - View Document